NASDAQ OMX

Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates

Dela

WALTHAM, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2017.

"We recently had a meeting with the U.S. Food and Drug Administration (FDA) to obtain feedback and guidance related to the Phase III clinical development of MIN-101 as a treatment for negative symptoms of schizophrenia," said Dr. Remy Luthringer, president and chief executive officer of Minerva. "We expect to initiate Phase III development of this compound in the second half of 2017."

Clinical Development Updates

MIN-101:

  • An "end-of-Phase II meeting" with the FDA took place recently to review pre-clinical and clinical data generated to date with MIN-101 and to discuss Phase III and Phase IV clinical development of this compound to treat negative symptoms in patients with a diagnosis of schizophrenia, including pivotal trial design.    

MIN-117:

  • Following the acceptance of the Investigational New Drug application (IND) for MIN-117 by the FDA late last year, Minerva is planning clinical trials with this compound in the U.S. and Europe.  These trials will build upon the results from the Phase IIa trial with MIN-117, and they are expected to begin in late 2017.

MIN-202 (JNJ-42847922), under joint development with Janssen Pharmaceutica NV (Janssen):

  • The planned indications for the next stage of clinical development with MIN-202 include insomnia without neuro-psychiatric comorbid symptoms and comorbid insomnia in patients suffering from depressive disorders.  A number of supportive activities and clinical pharmacology studies are being conducted by Minerva and Janssen in preparation for trials in both indications.

First Quarter 2017 Financial Results

  • Net Loss:  Net loss was $10.6 million for the first quarter of 2017, or a loss per share of $0.30 (basic and diluted), compared to a net loss of $8.0 million, or a loss per share of $0.29 (basic and diluted) for the first quarter of 2016.
     
  • R&D Expenses: Research and development (R&D) expenses were $7.6 million in the first quarter of 2017, compared to $5.4 million in the first quarter of 2016.  R&D expense in the three month periods ended March 31, 2017 and 2016 included non-cash stock based compensation expenses of $0.5 million and $0.2 million, respectively.  This increase in R&D expenses primarily reflects higher development expenses under the MIN-202 program for Phase II clinical trial preparation and an increase in non-cash, stock-based compensation expenses.  These amounts were partially offset by lower costs due to the completion of our Phase IIb clinical trial of MIN-101 and the completion of our Phase IIa clinical trial of MIN-117. 
     
  • G&A Expenses: General and administrative (G&A) expenses were $2.9 million in the first quarter of 2017, compared to $2.4 million in the first quarter of 2016.  G&A expense in the three month periods ended March 31, 2017 and 2016 included non-cash stock-based compensation expenses of $0.8 million and $0.6 million, respectively. This increase in general and administrative expenses was primarily due to an increase in legal and professional fees, an increase in non-cash stock-based compensation expenses, and increased personnel costs during the three months ended March 31, 2017.
     
  • Cash Position: Cash, cash equivalents and marketable securities as of March 31, 2017 were approximately $85.4 million.  The Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to meet its cash commitments for at least the next 12 months. 

Conference Call Information:

Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities.  To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 2971783.

The live webcast can be accessed under "Events and Presentations" in the Investors and Media section of Minerva's website at ir.minervaneurosciences.com.  The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson's disease.  Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."  For more information, please visit www.minervaneurosciences.com

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and results of future clinical milestones with MIN-101, MIN-202 and MIN-117, including the planned Phase III trial of MIN-101, the timing and scope of future clinical trials and results of clinical trials with these compounds; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether any of our therapeutic products will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether the results of future clinical trials of any of our therapeutic products, if any, will be consistent with the results of past clinical trials; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; our ability to achieve the results contemplated by our co-development agreements; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed with the Securities and Exchange Commission on May 4, 2017.  Copies of reports filed with the SEC are posted on our website at  www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.



CONDENSED CONSOLIDATED BALANCE SHEET DATA
(Unaudited)
  March 31, December 31,
  2017     2016  
  (in thousands)
ASSETS
Current Assets:    
Cash and cash equivalents $   68,895   $   82,981  
Marketable securities     16,465       -   
Restricted cash     80       80  
Prepaid expenses and other current assets     792        803  
Total current assets     86,232       83,864  
Equipment, net     6       10  
In-process research and development     34,200       34,200  
Goodwill     14,869       14,869  
Total Assets $   135,307   $   132,943  
     
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:    
Notes payable - current portion $   4,959   $   4,854  
Accounts payable     3,276       1,467  
Accrued expenses and other current liabilities     1,673       816  
             
Accrued collaborative expenses     3,078       2,548  
             
Total current liabilities     12,986       9,685  
     
Long-Term Liabilities:    
Notes payable - noncurrent     2,601       3,841  
Deferred taxes      13,434       13,434  
Total liabilities     29,021       26,960  
Stockholders' Equity:    
Common stock     4       4  
Additional paid-in capital     249,785       238,837  
Accumulated deficit     (143,503 )     (132,858 )
Total stockholders' equity     106,286       105,983  
Total Liabilities and Stockholders' Equity $   135,307   $   132,943  

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)      
    Three Months Ended March 31,
     
    (in thousands, except per share amounts)
      2017     2016  
       
Revenues   $   -    $   -   
Operating expenses:      
Research and development       7,614       5,375  
General and administrative       2,871       2,382  
Total operating expenses       10,485       7,757  
       
Foreign exchange losses       (17 )     (9 )
Investment income       59       32  
Interest expense       (202 )     (270 )
Net loss   $   (10,645 ) $   (8,004 )
Loss per share:      
Basic and diluted   $   (0.30 ) $   (0.29 )
Weighted average shares:      
Basic and diluted       35,370       27,203  

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Marcus Hiles - Texas Takes #1 Four Years in a Row in America's Top States for Business19.7.2018 23:39Pressmeddelande

DALLAS, July 19, 2018 (GLOBE NEWSWIRE) -- The future business scene in Texas is looking brighter than ever as the state continues to hold its place as a national leader. Growth is spreading across areas such as North Texas, Houston and San Antonio with businesses quickly expanding their operations in the state that offers some of the best in business-friendly climates and overall growth potential. Tapping into the market recently are global leaders such as Toyota, Liberty Mutual and JP Morgan who have taken advantage of the state's increasing network of commercial properties, workforce and business resources. Named by CNBC for the fourth consecutive year as America's Top State for Business, Texas scored above all 50 states on overall business competitiveness. With the business hub building on its role as a national leader for the past decade, this top rank title reflects the progress Texas has made in cementing its place in the global economy. "This national recognition comes without s

Second Quarter 2018 Results Conference Call19.7.2018 21:34Pressmeddelande

AURORA, Ontario, July 19, 2018 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX:MG) (NYSE:MGA) SECOND QUARTER 2018 RESULTS CONFERENCE CALL WEDNESDAY - AUGUST 8th, 2018 7:30 AM ET DIAL IN NUMBERS North America Toll Free: International Toll: Webcast: 1-888-223-4641 1-416-981-9080 www.magna.com Slide presentation will be available on our website prior to the call. REBROADCAST INFORMATION Replay available 2 hours after the call until August 15, 2018 North America Toll Free: International Toll: Reservation No.: 1-800-558-5253 1-416-626-4100 21892829 INVESTOR CONTACT Louis Tonelli, Vice-President, Investor Relations louis.tonelli@magna.com, 905-726-7035 TELECONFERENCE CONTACT Nancy Hansford, Executive Assistant, Investor Relations nancy.hansford@magna.com, 905-726-7108 This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originali

Uganda National Airlines Company Limited Signs Firm Order for Four Bombardier CRJ900 Aircraft19.7.2018 18:36Pressmeddelande

First operator of the new CRJ Series ATMOSPHÈRE cabin in Africa MONTREAL, July 18, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft announced today that it has signed a firm order for four new CRJ900 regional jets with Uganda National Airlines Company. Based on the list price for the CRJ900 aircraft, the firm order is valued at approximately US$190 million. "We congratulate the Government of Uganda for the revival of its national flag carrier, and are thrilled that the new airline has selected Bombardier and the CRJ900 regional jets for its upcoming debut," said Jean-Paul Boutibou, Vice President, Sales, Middle-East and Africa, Bombardier Commercial Aircraft. "Recognized for its superior economics and efficiency, the CRJ Series aircraft have enabled airlines worldwide to serve communities with better connectivity, and we look forward to supporting the development of Uganda's regional air travel with these CRJ900 regional jets." Uganda Airlines will operate the CRJ900 in dual-cla

CrownBio Supports Excellence in Translational Research with Grant Award that Funds Innovative PDX Model Development in Immuno-Oncology19.7.2018 15:03Pressmeddelande

"Cancer Research Center of Lyon iPS novel PDX models formulate new immune cell focused strategies" SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, is proud to announce the award of its Patient-Derived Xenograft (PDX) grant program to doctors Fabrice Lavial, Christophe Caux and Bertrand Dubois from the Cancer Research Center of Lyon (CRCL). The grant program was established to support oncology researchers pursuing scientific advancements in cancer using PDX technology. Following an extensive review, CrownBio's Scientific Steering Committee selected Dr. Lavial and his colleagues at the CRCL due to their project's potential to create breakthroughs in preclinical oncology strategies. Their research combines PDX and iPS cell technologies to create patient-specific, humanized models. These unique models wil

Jumio Introduces Liveness Detection for Web to Better Deter Fraud During Account Onboarding19.7.2018 14:00Pressmeddelande

New identity proofing functionality ensures that the person behind a Web upload verification is present and the person actually creating a new online account PALO ALTO, Calif., July 19, 2018 (GLOBE NEWSWIRE) -- Jumio, the creator of Netverify(TM) Trusted Identity as a Service (TIaaS), today announced the addition of Liveness Detection for Web to better thwart fraudsters' evolving and sophisticated attempts to assume another individual's identity. With identity verification, Jumio's approach is to first verify the government-issued ID (e.g., driver's license, passport or ID card) and ensure that it is authentic and has not been doctored. For mobile SDK customers, Jumio then requires the user to take a selfie which enables the company to compare the person in the selfie to the person pictured in the ID document. Since Netverify is an omnichannel solution, Jumio also supports identity verification via desktop webcams. This channel enables our customers to reach large market segments who a

Northland Power Adds 17MW of Capacity to the Deutsche Bucht Offshore Wind Farm19.7.2018 12:33Pressmeddelande

TORONTO, July 19, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. ("Northland") (TSX:NPI) announced today that the Deutsche Bucht Mono Bucket pilot demonstrator ("Demo") project has reached financial close. All required funds for the Demo project have been contributed by Northland and committed by the project lenders. In May, the Federal Maritime and Hydrographic Agency of Germany (BSH) granted the Deutsche Bucht offshore wind project the permit required to erect two additional pilot wind turbines using Mono Bucket foundations. Deutsche Bucht will be the first offshore wind farm worldwide to test this new type of foundation structure under commercial operating conditions. As previously announced, the two turbines will contribute an additional 17 MW of capacity to the base 252 MW project for a total of 269 MW and bringing the total project cost to approximately €1.4 billion (CAD $2.0 billion) - up from €1.3 billion. Northland's corporate investment has increased from approximately $400 mi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum